Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study.

Ana López GonzálezSonia Del Barco BerrónIsabel GrauMaria GalanBeatriz Castelo Fernández Cortes Salgado AlfonsoPedro Sánchez RoviraAlejandro Martinez-BuenoXavier GonzalezAlmudena GarcíaPetra GenerLeonardo Mina Daniel Alcalá-LópezMiguel SampayoJavier CortesJosé Manuel Pérez-GarciaAntonio Llombart-CussacElena López-Miranda

Published in: Cancers (2022)

Eribulin + AI does not seem to improve outcomes compared with eribulin monotherapy in patients with AI-resistant luminal ABC. This chemo-endocrine approach deserves further investigation after progression to CDK4/6i-based therapy.

Keyphrases

metastatic breast cancer
artificial intelligence
phase ii
combination therapy
open label
cell cycle
clinical trial
type diabetes
metabolic syndrome
machine learning
cancer therapy
randomized controlled trial
deep learning
skeletal muscle
locally advanced
weight loss
cell therapy
rectal cancer